A study of two tumor markers across glioma grades
Original title: Clinicopathological Implications of IDH1 Mutation and Ki-67 Expression Across WHO Grades of Gliomas: Insights from a Prospective Observational Study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked at tumor samples from people, but it did not test any treatment.
The short version
Doctors looked at two lab markers in 90 brain tumors to see how they match the tumor's grade.
What was studied. Doctors studied tissue from 90 people with a brain tumor called glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary. They checked each sample for a gene change called IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary R132H and for a marker called Ki-67: A stain that shows how many tumor cells were dividing when the sample was taken. The report gives it as a percentage. It is read together with everything else, not on its own. See the glossary, which shows how fast cells are growing.
What they found. Most tumors were astrocytomas, 55 of 90, and 24 of 90 were glioblastomas. The IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary gene change was found in 65 of 90 cases. It was found in all 28 grade II tumors, 8 of 9 grade I tumors, and 20 of 26 grade III tumors. Only 9 of 27 grade IV glioblastomas had it. Ki-67: A stain that shows how many tumor cells were dividing when the sample was taken. The report gives it as a percentage. It is read together with everything else, not on its own. See the glossary was higher in higher grades, above 20% in 26 of 27 grade IV tumors. Tumors with the IDH1 change tended to have lower Ki-67. Younger age was linked to having the IDH1 change, and older age was linked to not having it.
What this means, and what it doesn't
What it could mean: These two markers are already part of how doctors sort brain tumors. This study supports checking both. If you have had surgery or a biopsy, your report may list IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary and Ki-67: A stain that shows how many tumor cells were dividing when the sample was taken. The report gives it as a percentage. It is read together with everything else, not on its own. See the glossary. Your doctor can explain what your own results mean for you.
What it doesn't mean: This is not a new treatment, and it is not a cure. The study only looked at tumor tissue and lab markers. It did not follow people over time, so it cannot say how long anyone lived or who did better. The authors say these are links only, not proven predictions about the future. Larger studies that track people over time are still needed.
Source: PubMed, August 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.